Alginate, a viscous polysaccharide from mucoid Pseudomonas aeruginosa, may interfere with the host defenses in patients with cystic fibrosis and chronic P. aeruginosa lung infection. The alginate concentration in the sol phase of expectorated sputum was quantitated by a biochemical method and a newly developed enzyme-linked immunosorbent assay. There was a high degree of correlation between the methods, and the concentration of alginate ranged from 4 to 101 Fig/ml with a median of 35.5 ,ug/ml when measured by enzyme-linked immunosorbent assay. Alginate could not be detected in the bronchial secretions from patients without P. aeruginosa infection. In vitro investigation of alginate did not show any activation of the alternative pathway of complement, as determined by a hemolytic kinetic assay and by testing for neutrophil chemotaxis. At a high concentration, P. aeruginosa alginate caused a slight activation of the classical pathway of complement. Alginate did not cause neutrophil chemotaxis by itself but was able to reduce the neutrophil chemotactic response to N-formylmethionylieucylphenylalanine and for zymosan-activated serum. P. aeruginosa and seaweed alginates were able to prime neutrophils for increased N-formylmethionylieucylphenylalanine-induced neutrophil oxidative burst, as determined by chemiluminescence. Because of its ability to prevent attraction of neutrophils to the site of infection, lack of complement activation, and ability to enhance neutrophil oxidative burst, alginate from P. aeruginosa may contribute to the persistence and pathogenesis of chronic P. aeruginosa infection in cystic fibrosis.
Mucoid Pseudomonas aeruginosa is characteristically associated with chronic lung infection in patients with cystic fibrosis (CF) (5) , where up to 80% of the patients may harbor mucoid strains. Mucoid P. aeruginosa infection is associated with a pronounced antibody response and a poor prognosis (15) , whereas infection with nonmucoid strains seems to be less virulent in CF patients (11) . Presumably, there exists a selective survival advantage which favors the chronic persistence of mucoid strains despite a vigorous immune response (29) and normal phagocytic cell function (41) in CF patients. The mucoid substance, a hydrophilic polyanionic polysaccharide, alginate, is therefore considered one of the virulence factors produced by P. aeruginosa (13) .
Once established in the lungs, P. aeruginosa exists in the form of mucoid microcolonies (21) , and it is rarely eliminated despite an abundance of phagocytic cells in bronchial secretions, mainly represented by polymorphonuclear leukocytes (PMNs) (43) . It has been shown that mucoid strains are phagocytosed less readily than nonmucoid strains (1, 8) . After treatment with alginase, the phagocytosis of mucoid strains by human monocytes was similar to that of nonmucoid strains (6) . By using a crude alginate extract, Schwartzman and Boring (38) found that phagocytosis by rabbit PMNs of one mucoid strain is inhibited, whereas no effect is seen when testing phagocytosis of a nonmucoid strain.
Mucoid strains are not phagocytosed by rabbit alveolar macrophages (32) , and an inhibitory effect of alginate on the uptake of P. aeruginosa by monocytes (27, 39) has been demonstrated, which was suggested to be caused by the viscous nature of alginate (39) .
The clinical correlation of the above findings is not entirely * Corresponding author.
clear, since the concentration of alginate in the lungs is unknown. In this study, we have estimated the concentration of alginate in sol phase of bronchial secretions and used purified alginate preparations to further investigate the interaction of P. aeruginosa alginate with complement and PMNs in vitro.
MATERIALS AND METHODS
Sputum samples. Bronchial secretions were collected by expectoration for 30 to 60 min from 22 patients with cystic fibrosis and chronic P. aeruginosa lung infection and ultracentrifuged for 4 h at 105,000 x g at 4°C according to a previously described procedure (36) . The sol phase samples were stored at -20°C until analysis. Sputa from nine patients with chronic lung disease but without P. aeruginosa infection were treated in a similar way and used as controls.
Purified P. aeruginosa alginate. Alginate was purified from two isolates of mucoid P. aeruginosa obtained from bronchial secretions from two patients with CF (strains 8754 and 9721 [28] ). Briefly, the organisms were grown on a solid medium for 72 h at 35°C; the mucoid material was scraped off, centrifuged, heated to 80°C for 30 min, precipitated twice with ethanol to a final concentration of 80% (vol/vol), washed repeatedly with ethanol, dissolved in phosphatebuffered saline, digested with nucleases, precipitated with ethanol and fractionated by ion exchange chromatography on a DEAE-Sephacel (Pharmacia, Uppsala, Sweden) column with an ammonium carbonate gradient from 0.05 to 1 M. Fractions containing uronic acid in the carbazole-borate assay (20) were pooled, dialyzed, and freeze-dried. The alginate content was 100% when compared with a standard of seaweed alginate. Previously, the alginate preparations have been shown to contain only trace amounts of protein and lipopolysaccharide (LPS) that had no immunological reactivity (28) .
Seaweed alginate. Commercial seaweed alginate was obtained from Grindsted Products, Brabrand, Denmark.
Alginate concentration in sputum. (i) Carbazole assay. Sol phase samples (0.5 ml) were heated to 80°C for 15 min and centrifuged, and the supernatant was dialyzed against 0.9% saline. Cold ethanol was added slowly to a final concentration of 80% (vol/vol), and various amounts of a whitish precipitate were formed. After 1 h at 4°C, the mixture was centrifuged, the supernatant was discarded, and the pellet was dissolved in 0.5 ml of isotonic saline. Uronic acid content was analyzed by the carbazole-borate method (20) with mannuronolactone (Sigma Chemical Co., St. Louis, Mo.) as an internal standard, and the A530 was read.
(ii) ELISA. A competitive enzyme-linked immunosorbent assay (ELISA) was developed to measure the concentration of alginate in secretions. Rabbits were immunized for 3 months with a mixture of three immunologically crossreactive P. aeruginosa alginate preparations (28) , and immunoglobulin G and immunoglobulin A were purified by precipitation with ammonium sulfate and ion-exchange chromatography (10 significantly higher than the concentration of alginate in control sol phase samples, in which alginate could not be detected (Fig. 2) .
The volume of a microcolony was calculated to be between 1.16 to 9.5 pA, assuming that the volume of the segment ranged from one-fifth to one-half of the volume of a sphere. The corresponding concentration of alginate in a colony ranged from approximately 3 to 0.4 mg/ml.
Interaction of alginate with complement. Neither of the two tested purified alginates were able to activate the classical or the alternative pathway of the complement cascade at a concentration of 240 p.g/ml, but a slight activation of the classical pathway was found at 1,000 jig/ml. The degree of activation was modest, albeit exceeding the analytical variation of the assay, and it corresponded to a reduction of serum hemolytic activity of 7%.
Effect of alginate on PMN chemotaxis. The two alginate preparations were not able to attract PMNs at a concentration of 1 mg/ml, irrespective of whether they were mixed with buffer or fresh human serum. The response was less than 2% of that of the positive control of ZAS and comparable with that of buffer alone. scavenge free radicals released from neutrophils (22, 40) . The inhibitory activity of alginate on host phagocytic cell function may give alginate-producing, mucoid strains of P. aeruginosa a survival advantage in the lungs of patients with CF. This may explain the chronicity of the infection. Also, it has been suggested that alginate, by its physicochemical properties, may contribute to the increased viscosity of airway secretions that is characteristic for patients with CF (33) .
All of these observations are, however, based on in vitro experiments, and the concentrations used have been arbitrary because alginate has never been quantitated in lung (12) showed P. aeruginosa to be mucoid in vivo in CF lungs. By electron microscopy, the bacteria reside in vivo encased in an extensive polysaccharide matrix of mucoid microcolonies (21) . With an immunofluorescence technique, two CF lung autopsy specimens reacted with a monoclonal antibody specific for P. aeruginosa alginate (42) . Our study showed that alginate was detectable by ELISA and by the carbazole-borate assay of expectorated sputum from patients with CF and chronic P. aeruginosa infection and could be quantitated. These direct observations are furthermore confirmed by finding antialginate antibodies in serum from patients with CF (4, 28, 31) , which provides evidence for in vivo production of alginate in the CF lung. Only one other report exists in which alginate has been quantitated in biological fluids; a patient with meningitis with a mucoid strain of P. aeruginosa had a uronic acid concentration in the cerebrospinal fluid of 40 ,ug/ml, measured by the carbazole-borate method (44) . By using the same biochemical methods, we showed in this study that the sol phase samples of expectorated sputum of CF patients contained alginate in concentrations ranging from 1 to 100 ,ug/ml, with a median value of approximately 40 ,ug/ml. These concentrations in the sputum will not, considering the almost normal level of divalent cations in lung secretions (19, 23) , cause the alginate to become highly viscous, and we therefore conclude that at these concentrations, alginate probably does not contribute very much to the stickiness of CF sputum.
The carbazole-borate assay is sensitive to impurities (20) .
The results of the chemical assay were therefore confirmed by developing an inhibition ELISA by using hyperimmune rabbit antialginate immunoglobulins. The correlation between these two independent tests was very high (Fig. 2) . The ELISA may therefore be useful for measuring alginate in biological fluids in which contaminants may interfere with the specificity of the chemical method.
The concentration of alginate measured in sputum is representative only of that found in the larger airways, but, because of dilution with host secretions, the figure does not necessarily reflect the highest concentration of alginate that may be found in the lungs. By calculating the alginate content of in vitro colonies, we assume that the concentration of in vivo mucoid microcolonies is at least 10-fold higher than that in the larger airway secretions. In order to investigate the interaction of alginate with the immune cells of the host, a range of alginate concentrations will therefore have to be employed.
Activation of complement provides the host with a way of protecting itself against invading microorganisms, and activation can be triggered by bacterial carbohydrates such as LPS (24) or peptidoglycan (30) . We tested the ability of purified P. aeruginosa alginate to activate complement in two different assays. The first assay was a hemolytic kinetic assay in which the ability to form the lytic C5b9 complex was assessed, and the second was a neutrophil chemotactic assay in which C5a-driven chemotaxis was determined. The two alginate preparations tested were unable to activate the alternative pathway in the hemolytic assay, and only at a very high concentration did alginate activate the classical pathway slightly. When mixed with fresh normal serum as the complement source, no neutrophil chemotaxis was observed, confirming the inability of alginate to activate complement. LPS activates the alternative pathway (24) , and our results indicate that the alginate preparations were free of biologically active LPS. Sputum sol phase samples from CF patients infected with P. aeruginosa have been shown to contain split products of complement component C3, which was seen as evidence of complement activation occurring in vivo in the lungs (37) . It has also been found that mucoid P. aeruginosa can activate complement (34) (9) , and it has previously been demonstrated that the heat-stable fraction of sputum sol phase samples from CF patients also is able to prime neutrophils (18) . On the basis of the current data, alginate could, together with LPS, account for this effect.
The progressive damage to pulmonary tissue is probably due to an immune complex-mediated, complement-triggered release of endogenous host proteases and toxic oxygen radicals from neutrophils, as is typical of a type III hypersensitivity reaction (14, 25, 35 
